High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection

Peter Mu Hsin Chang, Yi Chen Yeh, Tzu Chi Chen, Yu Chung Wu, Pei-Jung Lu, Hui Chuan Cheng, Hsueh Ju Lu, Ming Huang Chen, Teh Ying Chou, Chi Ying F. Huang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths around the world, and a high recurrence rate after complete resection is an important issue reducing the cure rate and survival of patients with early stage NSCLC. Several pathologic biomarkers are associated with recurrence in early stage lung cancer after complete resection. Methods: We evaluated the expression and prognostic value of the α1 subunit of the nicotinic acetylcholine receptor (CHRNA1) as well as other pathologic features of tumor tissues resected from patients with stage I adenocarcinoma of the lung. Results: A high ratio (173/185) of CHRNA1 expression (93.5 %) was found in stage I lung adenocarcinoma. In the multivariate survival analysis, tumor necrosis, angiolymphatic invasion, perineural invasion, and CHRNA1 expression were independent poor prognostic factors for both recurrence-free and overall survival (OS). Patients expressing CHRNA1 had worse median recurrence-free survival (60.6 vs. 77.9 months, P = 0.03) and OS (65.1 vs. 77.9 months, P = 0.04) compared with CHRNA1-negative patients. Conclusions: CHRNA1 expression could be directly tested from the tumor after complete resection. In early stage NSCLC, it could be a useful prognostic factor for recurrence and survival.

Original languageEnglish
Pages (from-to)3648-3654
Number of pages7
JournalAnnals of Surgical Oncology
Volume20
Issue number11
DOIs
Publication statusPublished - 2013 Oct 1

Fingerprint

Recurrence
Survival
Non-Small Cell Lung Carcinoma
Neoplasms
Nicotinic Receptors
Survival Analysis
Cause of Death
Lung Neoplasms
Necrosis
Multivariate Analysis
Survival Rate
Biomarkers
Adenocarcinoma of lung

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Chang, Peter Mu Hsin ; Yeh, Yi Chen ; Chen, Tzu Chi ; Wu, Yu Chung ; Lu, Pei-Jung ; Cheng, Hui Chuan ; Lu, Hsueh Ju ; Chen, Ming Huang ; Chou, Teh Ying ; Huang, Chi Ying F. / High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 11. pp. 3648-3654.
@article{27e63b4a737c40d7b49210cb57718ce5,
title = "High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection",
abstract = "Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths around the world, and a high recurrence rate after complete resection is an important issue reducing the cure rate and survival of patients with early stage NSCLC. Several pathologic biomarkers are associated with recurrence in early stage lung cancer after complete resection. Methods: We evaluated the expression and prognostic value of the α1 subunit of the nicotinic acetylcholine receptor (CHRNA1) as well as other pathologic features of tumor tissues resected from patients with stage I adenocarcinoma of the lung. Results: A high ratio (173/185) of CHRNA1 expression (93.5 {\%}) was found in stage I lung adenocarcinoma. In the multivariate survival analysis, tumor necrosis, angiolymphatic invasion, perineural invasion, and CHRNA1 expression were independent poor prognostic factors for both recurrence-free and overall survival (OS). Patients expressing CHRNA1 had worse median recurrence-free survival (60.6 vs. 77.9 months, P = 0.03) and OS (65.1 vs. 77.9 months, P = 0.04) compared with CHRNA1-negative patients. Conclusions: CHRNA1 expression could be directly tested from the tumor after complete resection. In early stage NSCLC, it could be a useful prognostic factor for recurrence and survival.",
author = "Chang, {Peter Mu Hsin} and Yeh, {Yi Chen} and Chen, {Tzu Chi} and Wu, {Yu Chung} and Pei-Jung Lu and Cheng, {Hui Chuan} and Lu, {Hsueh Ju} and Chen, {Ming Huang} and Chou, {Teh Ying} and Huang, {Chi Ying F.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1245/s10434-013-3034-2",
language = "English",
volume = "20",
pages = "3648--3654",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "11",

}

Chang, PMH, Yeh, YC, Chen, TC, Wu, YC, Lu, P-J, Cheng, HC, Lu, HJ, Chen, MH, Chou, TY & Huang, CYF 2013, 'High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection', Annals of Surgical Oncology, vol. 20, no. 11, pp. 3648-3654. https://doi.org/10.1245/s10434-013-3034-2

High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection. / Chang, Peter Mu Hsin; Yeh, Yi Chen; Chen, Tzu Chi; Wu, Yu Chung; Lu, Pei-Jung; Cheng, Hui Chuan; Lu, Hsueh Ju; Chen, Ming Huang; Chou, Teh Ying; Huang, Chi Ying F.

In: Annals of Surgical Oncology, Vol. 20, No. 11, 01.10.2013, p. 3648-3654.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection

AU - Chang, Peter Mu Hsin

AU - Yeh, Yi Chen

AU - Chen, Tzu Chi

AU - Wu, Yu Chung

AU - Lu, Pei-Jung

AU - Cheng, Hui Chuan

AU - Lu, Hsueh Ju

AU - Chen, Ming Huang

AU - Chou, Teh Ying

AU - Huang, Chi Ying F.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths around the world, and a high recurrence rate after complete resection is an important issue reducing the cure rate and survival of patients with early stage NSCLC. Several pathologic biomarkers are associated with recurrence in early stage lung cancer after complete resection. Methods: We evaluated the expression and prognostic value of the α1 subunit of the nicotinic acetylcholine receptor (CHRNA1) as well as other pathologic features of tumor tissues resected from patients with stage I adenocarcinoma of the lung. Results: A high ratio (173/185) of CHRNA1 expression (93.5 %) was found in stage I lung adenocarcinoma. In the multivariate survival analysis, tumor necrosis, angiolymphatic invasion, perineural invasion, and CHRNA1 expression were independent poor prognostic factors for both recurrence-free and overall survival (OS). Patients expressing CHRNA1 had worse median recurrence-free survival (60.6 vs. 77.9 months, P = 0.03) and OS (65.1 vs. 77.9 months, P = 0.04) compared with CHRNA1-negative patients. Conclusions: CHRNA1 expression could be directly tested from the tumor after complete resection. In early stage NSCLC, it could be a useful prognostic factor for recurrence and survival.

AB - Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths around the world, and a high recurrence rate after complete resection is an important issue reducing the cure rate and survival of patients with early stage NSCLC. Several pathologic biomarkers are associated with recurrence in early stage lung cancer after complete resection. Methods: We evaluated the expression and prognostic value of the α1 subunit of the nicotinic acetylcholine receptor (CHRNA1) as well as other pathologic features of tumor tissues resected from patients with stage I adenocarcinoma of the lung. Results: A high ratio (173/185) of CHRNA1 expression (93.5 %) was found in stage I lung adenocarcinoma. In the multivariate survival analysis, tumor necrosis, angiolymphatic invasion, perineural invasion, and CHRNA1 expression were independent poor prognostic factors for both recurrence-free and overall survival (OS). Patients expressing CHRNA1 had worse median recurrence-free survival (60.6 vs. 77.9 months, P = 0.03) and OS (65.1 vs. 77.9 months, P = 0.04) compared with CHRNA1-negative patients. Conclusions: CHRNA1 expression could be directly tested from the tumor after complete resection. In early stage NSCLC, it could be a useful prognostic factor for recurrence and survival.

UR - http://www.scopus.com/inward/record.url?scp=84883788499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883788499&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3034-2

DO - 10.1245/s10434-013-3034-2

M3 - Article

C2 - 23775407

AN - SCOPUS:84883788499

VL - 20

SP - 3648

EP - 3654

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 11

ER -